In fact, in AML, the use of demethylating agents such as Decitabine decreased methylation status of Wnt antagonist including SFRP1, HDPR1, and DKK3, providing evidence that activation of the pathway resulted from an epigenic silencing (Li et al., 2014). The gene discussed is SFRP1; the disease is acute myeloid leukemia.